CANTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Destination XL Group, Inc. (NASDAQ: DXLG), the largest integrated commerce ...

Enrollment completed in Phase 2a CBeyond™ trial of CB1 inhibitor, nimacimab, in obesity and overweight Faster-than-expected enrollment enables full top-line Phase 2a data in late Q3/early Q4 2025, ...